ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age

This study has been completed.

Sponsored by: National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00386789
  Purpose

Typhoid fever remains an important cause of morbidity and mortality in the developing world. It is estimated that more than 16 million cases and about 600,000 deaths occur annually, most of which occur in Southeast Asia and Africa. Ingestion of food or water contaminated by acutely infected persons or chronic carriers is the most common form of transmission. As a result, typhoid fever is prevalent where unsafe drinking water or contaminated food is common.

Typhoid fever is highly endemic in Vietnam, especially in the southern provinces and is a significant disease in both preschool and school-aged children. Data from Dong Thap Provincial Hospital, Mekong delta region showed that among 3,934 hospitalized typhoid fever cases from 1990 to 1995, 4.2% had complications and 0.8% died.

Typhoid fever has become difficult and expensive to treat. About 90% of Salmonella typhi isolates are of multidrug-resistant (resistant to chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole) and 76% of isolates showed reduced susceptibility to fluoroquinolones. Isolates with full fluoroquinolone or extended spectrum cephalosporin resistance have not yet reported in Vietnam but occur sporadically in the Indian subcontinent. If they become widespread, alternative treatment options will be limited. The improvement of sanitation, provision of safe water and elimination of chronic carriage is not expected to be achieved quickly. Accordingly, vaccination against typhoid fever is increasingly important national public health priority.


Condition
Typhoid Fever

MedlinePlus related topics:   Drinking Water    Fever   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Other
Official Title:   Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:   0
Study Start Date:   October 2006
Estimated Study Completion Date:   June 2008

Detailed Description:

Typhoid fever remains an important cause of morbidity and mortality in the developing world. It is estimated that more than 16 million cases and about 600,000 deaths occur annually, most of which occur in Southeast Asia and Africa. Ingestion of food or water contaminated by acutely infected persons or chronic carriers is the most common form of transmission. As a result, typhoid fever is prevalent where unsafe drinking water or contaminated food is common.

Typhoid fever is highly endemic in Vietnam, especially in the southern provinces, and is a significant disease in both preschool and school-aged children. Data from Dong Thap Provincial Hospital, Mekong delta region showed that among 3,934 hospitalized typhoid fever cases from 1990 to 1995, 4.2% had complications and 0.8% died.

Typhoid fever has become difficult and expensive to treat. About 90% of Salmonella typhi isolates are of multidrug-resistance (resistant to chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole) and 76% of isolates showed reduced susceptibility to fluoroquinolones. Isolates with full fluoroquinolone or extended spectrum cephalosporin resistance have not been reported yet in Vietnam but occur sporadically in the Indian subcontinent. If they become widespread, alternative treatment options will be limited. The improvement of sanitation, provision of safe water and elimination of chronic carriage are not expected to be achieved quickly. Accordingly, vaccination against typhoid fever is an increasingly important national public health priority.

  Eligibility
Ages Eligible for Study:   10 Years to 13 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria
  • INCLUSION CRITERIA:

Subjects who were involved in the Phase III trial, OH98-CH-N002.

EXCLUSION CRITERIA:

Not specified.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00386789

Locations
United States, Maryland
National Institute of Child Health and Human Development (NICHD), 9000 Rockville    
      Bethesda, Maryland, United States, 20892
Vietnam
Dong Thap Provincial Hospital    
      Dong Thap, Vietnam
Pasteur Institute    
      Ho Chi Minh City, Vietnam
National Institute of Hygiene and Epidemiology    
      Hanoi, Vietnam

Sponsors and Collaborators
  More Information

Publications:

Study ID Numbers:   999907004, 07-CH-N004
First Received:   October 11, 2006
Last Updated:   June 18, 2008
ClinicalTrials.gov Identifier:   NCT00386789
Health Authority:   United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Typhoid Fever  
Serological Survey  
Follow-Up  
Protection  
Typhoid Fever  

Study placed in the following topic categories:
Bacterial Infections
Fever
Antibodies
Enterobacteriaceae Infections
Salmonella Infections
Typhoid
Typhoid fever
Typhoid Fever
Gram-Negative Bacterial Infections

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers